0.7902
1.23%
-0.0098
Ensysce Biosciences Inc stock is currently priced at $0.7902, with a 24-hour trading volume of 125.52K.
It has seen a -1.23% decreased in the last 24 hours and a -13.73% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.8065 pivot point. If it approaches the $0.7869 support level, significant changes may occur.
Ensysce Biosciences Inc Stock (ENSC) Financials Data
Ensysce Biosciences Inc (ENSC) Net Income 2023
ENSC net income (TTM) was -$10.63 million for the quarter ending December 31, 2023, a +57.48% increase year-over-year.
Ensysce Biosciences Inc (ENSC) Cash Flow 2023
ENSC recorded a free cash flow (TTM) of -$10.78 million for the quarter ending December 31, 2023, a +39.73% increase year-over-year.
Ensysce Biosciences Inc (ENSC) Earnings per Share 2023
ENSC earnings per share (TTM) was -$5.30 for the quarter ending December 31, 2023, a +96.49% growth year-over-year.
Ensysce Biosciences Inc Stock (ENSC) Latest News
Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Why Netflix Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
Benzinga
Crude Oil Down 1%; Lockheed Martin Earnings Top Views
Benzinga
Why 3M Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Dow Tumbles 150 Points; Procter & Gamble Shares Rise On Upbeat Earnings
Benzinga
About Ensysce Biosciences Inc
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Cap:
|
Volume (24h):